Needham downgraded Inari from Buy to Hold
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/17/2024 | $75.00 | Outperform | Oppenheimer |
| 9/18/2024 | $50.00 | Hold | Stifel |
| 9/3/2024 | $47.00 | Market Perform | Leerink Partners |
| 8/9/2024 | $68.00 | Buy | Deutsche Bank |
| 7/25/2024 | Outperform | William Blair | |
| 7/18/2024 | Buy → Hold | Needham | |
| 2/29/2024 | $85.00 → $55.00 | Overweight → Neutral | Piper Sandler |
| 1/23/2024 | $72.00 | Buy | Needham |
Oppenheimer initiated coverage of Inari with a rating of Outperform and set a new price target of $75.00
Stifel initiated coverage of Inari with a rating of Hold and set a new price target of $50.00
Leerink Partners initiated coverage of Inari with a rating of Market Perform and set a new price target of $47.00
15-12G - Inari Medical, Inc. (0001531048) (Filer)
25-NSE - Inari Medical, Inc. (0001531048) (Subject)
S-8 POS - Inari Medical, Inc. (0001531048) (Filer)
Portage, Michigan, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, announced today that it has completed the acquisition of Inari Medical, Inc. (NASDAQ:NARI), a company that provides innovative solutions for venous thromboembolism (VTE) clot removal without the use of thrombolytic drugs. The addition of Inari brings an established peripheral vascular position to Stryker in the fast-growing VTE segment. "The acquisition of Inari Medical marks a significant milestone in expanding our interventional endovascular portfolio," said Kevin Lobo, Chair and Chief Executive Officer, Stryker. "We look forward to welcoming the talented Inari team to Stryk
NEW YORK, Feb. 13, 2025 /PRNewswire/ -- Kadant Inc. (NYSE:KAI) will replace Inari Medical Inc. (NASD: NARI) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, February 19. S&P 500 constituent Stryker Corp. (NYSE:SYK) is acquiring Inari Medical in a deal expected to be completed soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector February 19, 2025 S&P SmallCap 600 Addition Kadant KAI Industrials February 19, 2025 S&P SmallCap 600 Deletion Inari Medical NARI Health Care For more information about
Katie Szyman Appointed Chief Executive Officer and to Board of Directors Interim CEO Michelle Brennan Named Chairman of Masimo's Board Today the Board of Directors (the "Board") of Masimo (NASDAQ:MASI), a leading global medical innovator, announced that Katie Szyman has been appointed the next Chief Executive Officer ("CEO") of the Company. Interim CEO Michelle Brennan has been appointed Chairman of Masimo's Board and Lead Independent Director Quentin Koffey has been appointed Vice Chairman. All of these changes are effective as of February 12, 2025. Ms. Szyman is currently worldwide president of Advanced Patient Monitoring at BD (Becton, Dickinson and Company). Previously, Ms. Szyman
4/A - Inari Medical, Inc. (0001531048) (Issuer)
4 - Inari Medical, Inc. (0001531048) (Issuer)
4 - Inari Medical, Inc. (0001531048) (Issuer)
4 - Inari Medical, Inc. (0001531048) (Issuer)
4 - Inari Medical, Inc. (0001531048) (Issuer)
SC 13G/A - Inari Medical, Inc. (0001531048) (Subject)
SC 13G/A - Inari Medical, Inc. (0001531048) (Subject)
SC 13G/A - Inari Medical, Inc. (0001531048) (Subject)
NEW YORK, Feb. 13, 2025 /PRNewswire/ -- Kadant Inc. (NYSE:KAI) will replace Inari Medical Inc. (NASD: NARI) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, February 19. S&P 500 constituent Stryker Corp. (NYSE:SYK) is acquiring Inari Medical in a deal expected to be completed soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector February 19, 2025 S&P SmallCap 600 Addition Kadant KAI Industrials February 19, 2025 S&P SmallCap 600 Deletion Inari Medical NARI Health Care For more information about
Katie Szyman Appointed Chief Executive Officer and to Board of Directors Interim CEO Michelle Brennan Named Chairman of Masimo's Board Today the Board of Directors (the "Board") of Masimo (NASDAQ:MASI), a leading global medical innovator, announced that Katie Szyman has been appointed the next Chief Executive Officer ("CEO") of the Company. Interim CEO Michelle Brennan has been appointed Chairman of Masimo's Board and Lead Independent Director Quentin Koffey has been appointed Vice Chairman. All of these changes are effective as of February 12, 2025. Ms. Szyman is currently worldwide president of Advanced Patient Monitoring at BD (Becton, Dickinson and Company). Previously, Ms. Szyman
Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS))) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the results from its 2024 Annual General Meeting
Portage, Michigan, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, announced today that it has completed the acquisition of Inari Medical, Inc. (NASDAQ:NARI), a company that provides innovative solutions for venous thromboembolism (VTE) clot removal without the use of thrombolytic drugs. The addition of Inari brings an established peripheral vascular position to Stryker in the fast-growing VTE segment. "The acquisition of Inari Medical marks a significant milestone in expanding our interventional endovascular portfolio," said Kevin Lobo, Chair and Chief Executive Officer, Stryker. "We look forward to welcoming the talented Inari team to Stryk
IRVINE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ:NARI) ("Inari"), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its third quarter ended September 30, 2024. Third Quarter Financial and Recent Business Highlights Generated revenue of $153 million in Q3 of 2024, up 21% over the same quarter of last year.GAAP operating loss was $13.6 million in Q3 of 2024, compared to a $2.1 million operating income in the same quarter of last year.Non-GAAP operating loss was $0.4 million in Q3 of 2024, compared to a $4.8 million non-GAAP operating income in t
IRVINE, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ:NARI) ("Inari"), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will release its third quarter 2024 financial results on Monday, October 28, 2024. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live earnings call via telephone by dialing 844-825-9789 for domestic callers or 412-317-5180 for international callers. The live webinar may be acc